



Media Releases » Torrent Pharma announces Q2 FY 14-15 results November 5th, 2014

Financial Highlights of Q2 FY14 & FY15					
Financial Highlights	Q2 FY14	Q2 FY15	Growth	YTD FY14	YTD FY15
Revenues	1,148	1,217	6%	5,099	5,293
EBITDA	367	345	-6%	1,341	1,313
% Domestic	85%	85%		85%	85%
YTD YTD Compound Growth	281	381	7%	355	442
% Domestic	75%	85%		75%	85%
PAT	187	198	6%	633	659
% Domestic	85%	85%		85%	85%

- For Q2 14-15 revenues were at Rs. 1,217 crores, up by 25% from Rs. 972 crores during the same period last year.
- EBITDA for Q214-15 was at Rs. 345 crores up by 83% from Rs. 189 crores during the same period last year.
- PAT for Q214-15 was at Rs. 198 crores up by 75% compared to Rs. 113 crores during the same period last year.

Performance Highlights of Q2 FY 15

- Domestic formulation business recorded revenues of Rs. 442 crores, growing by 49%.
 - > Current quarter includes sales from acquired Elder business. Excluding this sales growth for quarter would have been 17%.
 - > As per AIOCD; acquired Elder business growth was 18% compared to covered market growth of 7% on rolling quarter basis.

- International revenues grew by 17% to Rs. 673 crores. Adjusting for currency movements revenues grew by 21%.
 - > Revenues from US operations recorded growth of 45%.
 - > Operations in Brazil registered revenue growth of 28%.
 - > Revenues from Europe (incl. Heumann) recorded a growth of 5%.
 - > Revenues from Rest of the World including Russia & CIS & Mexico operations were flat.

Performance Highlights of H1 FY 15

- Domestic formulation business recorded revenues of Rs. 795 crores, growing by 30%.
 - > Current H1 includes sales from acquired Elder business. Excluding this sales growth for H1 would have been 15%.
- International revenues grew by 26% to Rs. 1406 crores. Adjusting for currency movements revenues grew by 24%.
 - > Revenues from US operations recorded growth of 91%.
 - > Operations in Brazil registered revenue growth of 20%.
 - > Revenues from Europe (incl. Heumann) recorded a growth of 11%.
 - > Revenues from Rest of the World including Russia & CIS & Mexico operations recorded a de growth of 6%.

About Torrent Pharma

Torrent Pharma, with an annual turnover of almost Rs. 4200 crores is the flagship Company of the Torrent Group. With many of its products ranking among the top 200 brands, Torrent continues to be at the forefront of the Indian pharmaceutical industry. Torrent has a full equipped Research Center, employing almost 600 scientists, to support the Companies operations and product pipeline for both Domestic and Overseas markets. The Companies manufacturing plants located at Indrad, Baddi & Sikkim have facilities to produce Formulations and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.